December 20, 2024

Will CAR T-Cell Therapy Be the Magic Bullet for My Multiple Myeloma?

“Intense pain on the right side of my lower rib cage, in 2020, sent me first to my chiropractor for relief and then to my primary care provider for tests. Because of the location of the pain, the chir...

The ASCO Post

December 20, 2024

In Treatment of Transplant-Ineligible Myeloma, Addition of Isatuximab Improves Outcomes

In the phase III IMROZ trial, the addition of the anti-CD38 monoclonal antibody isatuximab-irfc to bortezomib, lenalidomide, and dexamethasone (VRd) was more effective than VRd alone as initial therap...

The ASCO Post

December 20, 2024

Use of Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia

In a German phase III trial (CLL12), reported in the Journal of Clinical Oncology, Langerbeins et al found that ibrutinib prolonged the time to symptomatic disease in patients with early-stage chronic...

The ASCO Post

December 20, 2024

MRI-First Strategy May Be Safe for Prostate Cancer Detection

A magnetic resonance imaging (MRI)-first approach may be safe for prostate cancer detection.

The ASCO Post

December 19, 2024

KEYNOTE-811: Pembrolizumab Combination in First-Line Setting Improves Overall Survival in Gastric Cancer

In the final per-protocol analysis of the phase III KEYNOTE-811 trial, an overall survival benefit was shown by adding the PD-1 inhibitor pembrolizumab to trastuzumab and chemotherapy in treatment-nai...

The ASCO Post

December 19, 2024

FDA Approves Ensartinib for ALK- Positive Locally Advanced or Metastatic NSCLC

The U.S. Food and Drug Administration (FDA) recently approved the anaplastic lymphoma kinase (ALK) inhibitor ensartinib (Ensacove) for adults with ALK-positive locally advanced or metastatic non–small...

The ASCO Post

December 18, 2024

UICC, ICCP: Landmark Review of National Cancer Strategies Illuminates Progress, Persistent Challenges

In a new policy review, the Union for International Cancer Control (UICC) and International Cancer Control Partnership (ICCP) analyzed over 100 national cancer and noncommunicable disease plans, with ...

The ASCO Post

December 18, 2024

Pirtobrutinib May Improve Survival Outcomes in Pretreated Patients With CLL or SLL

Researchers have examined the efficacy of the noncovalent BTK inhibitor pirtobrutinib in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to findings prese...

The ASCO Post

December 18, 2024

Novel Formulation Used in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting

In a Chinese phase III trial (PROFIT) reported in the Journal of Clinical Oncology, Zhou et al evaluated use of a mixed-formulation fosrolapitant/palonosetron (HR20013) plus dexamethasone in preventin...

The ASCO Post